Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership

Related LGND
Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689
Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma

In a report published Monday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $23.00 to $26.00.

In the report, Rivkind noted, “On March 14 the company announced its license and global supply agreement with Spectrum Pharmaceuticals on Captisol-enabled Melphalan for the treatment of multiple myeloma. Ligand received a $3M upfront payment and negotiated a healthy double-digit royalty (we estimate 20%) in addition to $50M in milestones that will be based on multiple regulatory and commercial events such as NDA acceptance, FDA approval, and launch. Spectrum is also taking over development costs, effective immediately.”

Ligand Pharmaceuticals closed on Friday at $23.27.

Latest Ratings for LGND

Jul 2015Cantor FitzgeraldTerminatesHold
Jun 2015CJS SecuritiesMaintainsMarket Perform
Jun 2015Cantor FitzgeraldMaintainsHold

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings


Related Articles (LGND)

View Comments and Join the Discussion!

Get Benzinga's Newsletters